New Enterprise Associates

Intact Vascular, Inc. is a medical device company based in Wayne, Pennsylvania, focused on developing minimally invasive products for peripheral vascular procedures. Established in 2011, the company is known for its Tack Endovascular System, which enhances the results of peripheral balloon angioplasty in treating peripheral arterial disease (PAD) and critical limb ischemia (CLI). This innovative technology aims to improve clinical outcomes and quality of life for patients suffering from vascular diseases, offering physicians a new and effective treatment option. Intact Vascular is dedicated to creating safe, efficacious, and user-friendly medical devices for healthcare providers and their patients.

Vesper Medical is committed to developing safe, efficacious and easy-to-use products for patients with deep venous disease and the physicians who treat them. The company's core technology, the Vesper DUO Venous Stent System, is purpose-built for venous stenting, with an unmatched combination of strength and flexibility designed to meet the multiple anatomical challenges presented by vein mechanics. Vesper Medical is advancing the treatment of deep venous disease by creating a highly differentiated, purpose-built venous stent portfolio that addresses the multiple anatomical challenges presented by the iliac and femoral veins. It also develops minimally- invasive peripheral vascular products. Vesper Medical was founded in 2016 and is headquartered in Wayne, PA, USA.

Lungpacer Medical Inc. is a medical device company specializing in therapeutic solutions aimed at enhancing the treatment of critically ill patients who require mechanical ventilation. Founded in 2009 and headquartered in Vancouver, Canada, with an additional office in Exton, Pennsylvania, the company has developed the Lungpacer DPT System. This diaphragm pacing system utilizes a temporary, minimally invasive, transvascular nerve stimulation technique to activate the diaphragm muscle, preserving its strength and integrity. By addressing the significant health and cost challenges associated with mechanical ventilation in Intensive Care Units, Lungpacer Medical aims to improve patient outcomes and reduce hospital care costs. The technology is designed to restore negative pressure ventilation, offering a more physiological respiratory pattern and mitigating the harmful effects associated with positive pressure ventilation.

PhaseBio is a clinical-stage biopharmaceutical company focused on developing innovative therapies for endocrine and metabolic disorders, as well as cardiovascular diseases. The company leverages its proprietary elastin-like polypeptides (ELPs) technology to enhance the stability, bioavailability, and efficacy of proteins and peptides. Its lead candidate, PB1023, is in a phase 2b clinical trial for managing hyperglycemia in type 2 diabetes, with potential applications in obesity. Additionally, PhaseBio is advancing Vasomera, a candidate in phase 1 trials aimed at treating pulmonary arterial hypertension and heart failure. The company is also exploring PB2452, a novel reversal agent for the antiplatelet drug ticagrelor, and PB1046 for pulmonary arterial hypertension. With a commitment to addressing unmet medical needs, PhaseBio is headquartered in Malvern, Pennsylvania.

Intact Vascular, Inc. is a medical device company based in Wayne, Pennsylvania, focused on developing minimally invasive products for peripheral vascular procedures. Established in 2011, the company is known for its Tack Endovascular System, which enhances the results of peripheral balloon angioplasty in treating peripheral arterial disease (PAD) and critical limb ischemia (CLI). This innovative technology aims to improve clinical outcomes and quality of life for patients suffering from vascular diseases, offering physicians a new and effective treatment option. Intact Vascular is dedicated to creating safe, efficacious, and user-friendly medical devices for healthcare providers and their patients.

Complexa, Inc. is a biopharmaceutical company based in Berwyn, Pennsylvania, focused on developing treatments for severe and life-threatening diseases related to fibrosis and inflammation. Established in 2008, the company is advancing its lead compound, CXA-10, an oral nitrated fatty acid aimed at treating focal segmental glomerulosclerosis (FSGS) and pulmonary arterial hypertension (PAH). Complexa utilizes proprietary technologies that involve the synthesis of endogenous nitro-fatty acids, which serve as cell-signaling agents regulating key inflammatory pathways. This approach aims to enhance the body's natural mechanisms for resolving and repairing acute and chronic tissue injuries, with a focus on addressing various inflammatory, fibrotic, and central nervous system diseases.

Intact Vascular, Inc. is a medical device company based in Wayne, Pennsylvania, focused on developing minimally invasive products for peripheral vascular procedures. Established in 2011, the company is known for its Tack Endovascular System, which enhances the results of peripheral balloon angioplasty in treating peripheral arterial disease (PAD) and critical limb ischemia (CLI). This innovative technology aims to improve clinical outcomes and quality of life for patients suffering from vascular diseases, offering physicians a new and effective treatment option. Intact Vascular is dedicated to creating safe, efficacious, and user-friendly medical devices for healthcare providers and their patients.

Galera Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Malvern, Pennsylvania, dedicated to developing innovative therapies that aim to enhance the effectiveness of radiotherapy in cancer treatment. The company’s lead product candidate, avasopasem manganese (GC4419), is a small molecule dismutase mimetic currently undergoing Phase III clinical trials for the treatment of severe oral mucositis induced by radiation in patients with head and neck cancer. Additionally, it is being tested in Phase IIa trials for radiotherapy-induced esophagitis in lung cancer patients. Galera is also advancing a second candidate, GC4711, which is in Phase I/II trials targeting pancreatic and lung cancers. The company was founded in 2012 and is committed to addressing severe side effects associated with cancer treatments to improve patient outcomes.

Galera Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Malvern, Pennsylvania, dedicated to developing innovative therapies that aim to enhance the effectiveness of radiotherapy in cancer treatment. The company’s lead product candidate, avasopasem manganese (GC4419), is a small molecule dismutase mimetic currently undergoing Phase III clinical trials for the treatment of severe oral mucositis induced by radiation in patients with head and neck cancer. Additionally, it is being tested in Phase IIa trials for radiotherapy-induced esophagitis in lung cancer patients. Galera is also advancing a second candidate, GC4711, which is in Phase I/II trials targeting pancreatic and lung cancers. The company was founded in 2012 and is committed to addressing severe side effects associated with cancer treatments to improve patient outcomes.

Duolingo, Inc. is a language-learning platform founded in 2011 and headquartered in Pittsburgh, Pennsylvania. The company offers a free service that enables users to learn nearly 40 languages through 98 distinct courses, with an option for a premium subscription that provides additional features such as ad removal and offline access. Duolingo claims to have 30 million active users, making it a leading educational app globally. It also provides tailored solutions for educators through "Duolingo for Schools," which allows teachers to monitor student progress. The platform utilizes advanced data analytics and artificial intelligence to enhance the learning experience, incorporating engaging design elements to keep users motivated. Duolingo's revenue primarily derives from subscriptions, and it has emerged as a top-grossing app in the education category on both Google Play and the Apple App Store.

Intact Vascular, Inc. is a medical device company based in Wayne, Pennsylvania, focused on developing minimally invasive products for peripheral vascular procedures. Established in 2011, the company is known for its Tack Endovascular System, which enhances the results of peripheral balloon angioplasty in treating peripheral arterial disease (PAD) and critical limb ischemia (CLI). This innovative technology aims to improve clinical outcomes and quality of life for patients suffering from vascular diseases, offering physicians a new and effective treatment option. Intact Vascular is dedicated to creating safe, efficacious, and user-friendly medical devices for healthcare providers and their patients.

PhaseBio is a clinical-stage biopharmaceutical company focused on developing innovative therapies for endocrine and metabolic disorders, as well as cardiovascular diseases. The company leverages its proprietary elastin-like polypeptides (ELPs) technology to enhance the stability, bioavailability, and efficacy of proteins and peptides. Its lead candidate, PB1023, is in a phase 2b clinical trial for managing hyperglycemia in type 2 diabetes, with potential applications in obesity. Additionally, PhaseBio is advancing Vasomera, a candidate in phase 1 trials aimed at treating pulmonary arterial hypertension and heart failure. The company is also exploring PB2452, a novel reversal agent for the antiplatelet drug ticagrelor, and PB1046 for pulmonary arterial hypertension. With a commitment to addressing unmet medical needs, PhaseBio is headquartered in Malvern, Pennsylvania.

Strongbridge Biopharma plc is a commercial-stage biopharmaceutical company dedicated to developing and commercializing therapies for rare diseases with significant unmet medical needs. The company markets Keveyis, an oral carbonic anhydrase inhibitor used to treat various forms of primary periodic paralysis in the United States. Its clinical pipeline includes Recorlev, a cortisol synthesis inhibitor currently in Phase III trials for endogenous Cushing's syndrome, and Veldoreotide, a somatostatin analog that has completed Phase II trials for acromegaly. Founded in 1996 and based in Trevose, Pennsylvania, Strongbridge Biopharma aims to build its portfolio around rare endocrine disorders and plans to utilize a focused sales strategy to reach its target markets. The company is also actively seeking to in-license or acquire complementary products to enhance its rare disease franchise.

Duolingo, Inc. is a language-learning platform founded in 2011 and headquartered in Pittsburgh, Pennsylvania. The company offers a free service that enables users to learn nearly 40 languages through 98 distinct courses, with an option for a premium subscription that provides additional features such as ad removal and offline access. Duolingo claims to have 30 million active users, making it a leading educational app globally. It also provides tailored solutions for educators through "Duolingo for Schools," which allows teachers to monitor student progress. The platform utilizes advanced data analytics and artificial intelligence to enhance the learning experience, incorporating engaging design elements to keep users motivated. Duolingo's revenue primarily derives from subscriptions, and it has emerged as a top-grossing app in the education category on both Google Play and the Apple App Store.

Galera Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Malvern, Pennsylvania, dedicated to developing innovative therapies that aim to enhance the effectiveness of radiotherapy in cancer treatment. The company’s lead product candidate, avasopasem manganese (GC4419), is a small molecule dismutase mimetic currently undergoing Phase III clinical trials for the treatment of severe oral mucositis induced by radiation in patients with head and neck cancer. Additionally, it is being tested in Phase IIa trials for radiotherapy-induced esophagitis in lung cancer patients. Galera is also advancing a second candidate, GC4711, which is in Phase I/II trials targeting pancreatic and lung cancers. The company was founded in 2012 and is committed to addressing severe side effects associated with cancer treatments to improve patient outcomes.

Bravo Health, Inc. is a managed care provider that specializes in offering Medicare Advantage plans, including options tailored for special needs populations such as those receiving institutional care or individuals with chronic health conditions. The company also provides private fee-for-service plans, allowing members the flexibility to choose their healthcare providers, as well as Part D prescription drug plans for those requiring medication coverage. Bravo Health serves members across several states, including Delaware, Maryland, Pennsylvania, Texas, New Jersey, and Washington, D.C., and extends its prescription drug plans to 43 states. Founded in 1996 and based in Baltimore, Maryland, the company was formerly known as Elder Health, Inc.

Duolingo, Inc. is a language-learning platform founded in 2011 and headquartered in Pittsburgh, Pennsylvania. The company offers a free service that enables users to learn nearly 40 languages through 98 distinct courses, with an option for a premium subscription that provides additional features such as ad removal and offline access. Duolingo claims to have 30 million active users, making it a leading educational app globally. It also provides tailored solutions for educators through "Duolingo for Schools," which allows teachers to monitor student progress. The platform utilizes advanced data analytics and artificial intelligence to enhance the learning experience, incorporating engaging design elements to keep users motivated. Duolingo's revenue primarily derives from subscriptions, and it has emerged as a top-grossing app in the education category on both Google Play and the Apple App Store.

PhaseBio is a clinical-stage biopharmaceutical company focused on developing innovative therapies for endocrine and metabolic disorders, as well as cardiovascular diseases. The company leverages its proprietary elastin-like polypeptides (ELPs) technology to enhance the stability, bioavailability, and efficacy of proteins and peptides. Its lead candidate, PB1023, is in a phase 2b clinical trial for managing hyperglycemia in type 2 diabetes, with potential applications in obesity. Additionally, PhaseBio is advancing Vasomera, a candidate in phase 1 trials aimed at treating pulmonary arterial hypertension and heart failure. The company is also exploring PB2452, a novel reversal agent for the antiplatelet drug ticagrelor, and PB1046 for pulmonary arterial hypertension. With a commitment to addressing unmet medical needs, PhaseBio is headquartered in Malvern, Pennsylvania.

Trevena, Inc. is a biopharmaceutical company based in Chesterbrook, Pennsylvania, established in 2007. The company is dedicated to the development and commercialization of innovative medicines aimed at treating central nervous system disorders. Its product candidates include Oliceridine injection, which is designed for managing moderate-to-severe acute pain and has completed Phase III clinical trials, and TRV250, a delta-opioid receptor agonist that has finished Phase I trials for acute migraine treatment. Other candidates in development include TRV734, targeting both acute and chronic pain, and TRV027, which is being evaluated for acute heart failure. Additionally, Trevena is collaborating with Imperial College London to study TRV027 in the context of COVID-19. The company employs a specialized approach using G protein biased ligands to enhance the efficacy and safety of its therapeutics, addressing the limitations of existing GPCR-targeted drugs.

PhaseBio is a clinical-stage biopharmaceutical company focused on developing innovative therapies for endocrine and metabolic disorders, as well as cardiovascular diseases. The company leverages its proprietary elastin-like polypeptides (ELPs) technology to enhance the stability, bioavailability, and efficacy of proteins and peptides. Its lead candidate, PB1023, is in a phase 2b clinical trial for managing hyperglycemia in type 2 diabetes, with potential applications in obesity. Additionally, PhaseBio is advancing Vasomera, a candidate in phase 1 trials aimed at treating pulmonary arterial hypertension and heart failure. The company is also exploring PB2452, a novel reversal agent for the antiplatelet drug ticagrelor, and PB1046 for pulmonary arterial hypertension. With a commitment to addressing unmet medical needs, PhaseBio is headquartered in Malvern, Pennsylvania.

Trevena, Inc. is a biopharmaceutical company based in Chesterbrook, Pennsylvania, established in 2007. The company is dedicated to the development and commercialization of innovative medicines aimed at treating central nervous system disorders. Its product candidates include Oliceridine injection, which is designed for managing moderate-to-severe acute pain and has completed Phase III clinical trials, and TRV250, a delta-opioid receptor agonist that has finished Phase I trials for acute migraine treatment. Other candidates in development include TRV734, targeting both acute and chronic pain, and TRV027, which is being evaluated for acute heart failure. Additionally, Trevena is collaborating with Imperial College London to study TRV027 in the context of COVID-19. The company employs a specialized approach using G protein biased ligands to enhance the efficacy and safety of its therapeutics, addressing the limitations of existing GPCR-targeted drugs.

Vitae Pharmaceuticals is a clinical-stage biotechnology company based in Fort Washington, Pennsylvania, dedicated to discovering and developing novel small molecule drugs for diseases with significant unmet medical needs. Its pipeline includes VTP-43742, currently in Phase I clinical trials for autoimmune disorders such as psoriasis and multiple sclerosis; VTP-38543, in Phase IIa for atopic dermatitis; and BI 1147560, aimed at treating and preventing Alzheimer's disease. Additionally, the company is developing VTP-34072, which is in Phase II trials for type 2 diabetes, and VTP-38443 for acute coronary syndrome. Vitae Pharmaceuticals employs a structure-based drug-design platform, Contour, to create best-in-class compounds targeting large markets that include chronic kidney disease and atherosclerosis. Established in 2001, the company operates as a subsidiary of Allergan plc.

Rinera Networks is a professional in internet video distribution. It is based in Pittsburgh, Pennsylvania.

Vitae Pharmaceuticals is a clinical-stage biotechnology company based in Fort Washington, Pennsylvania, dedicated to discovering and developing novel small molecule drugs for diseases with significant unmet medical needs. Its pipeline includes VTP-43742, currently in Phase I clinical trials for autoimmune disorders such as psoriasis and multiple sclerosis; VTP-38543, in Phase IIa for atopic dermatitis; and BI 1147560, aimed at treating and preventing Alzheimer's disease. Additionally, the company is developing VTP-34072, which is in Phase II trials for type 2 diabetes, and VTP-38443 for acute coronary syndrome. Vitae Pharmaceuticals employs a structure-based drug-design platform, Contour, to create best-in-class compounds targeting large markets that include chronic kidney disease and atherosclerosis. Established in 2001, the company operates as a subsidiary of Allergan plc.

PPONEXT is a PPO services company that provides healthcare management and network services. PPONEXT offers access to a network of medical care providers, hospitals, and ancillary facilities to group health, workers' compensation, and other insurance payers in the Midwest, Texas, California, Florida, New Jersey, and Pennsylvania.